Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PG vs MRK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MRK Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 4–6 Matrix Metrics)

MRK Overall Winner 6-Pillar Tally: PG 3 – 3 MRK Matrix Metrics: PG 6 – 4 MRK

As of Nov 20, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Procter & Gamble Company (PG) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). PG carries a Unified Composite Score of 33.6/100 (SELL) at $169.37 (24.0x Forward P/E, 24.9% operating margin), whereas MRK carries 55.3/100 (HOLD) at $133.72 (14.9x Forward P/E, 35.2% operating margin).

  • Technical & Structure Timing Caution: PG trades in a Markup technical trend (SURGE options phase, RSI 61.0); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PG vs MRK
PG NYSE
Procter & Gamble Company
Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
$169.37
+0.91% 1D
Market Cap $389.0B
TTM Revenue $87.9B
Forward P/E 24.0x
Beta / 30D Vol 0.02β · 21% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 19.0 Fund 38.0 Flow 56.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 61
RSI-14: 61.0 · SMA20: $165.99 · SMA50: $156.84
MRK NYSE Head-to-Head Winner
Merck & Co., Inc.
Pharmaceutical Preparations
$133.72
+0.69% 1D
Market Cap $327.4B
TTM Revenue $67.4B
Forward P/E 14.9x
Beta / 30D Vol 0.23β · 34% Vol
Unified Composite Score
55.3 / 100 HOLD
Tech 36.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.9%), weak momentum, RSI 34
RSI-14: 34.0 · SMA20: $144.36 · SMA50: $145.28

6-Pillar Scorecard Institutional Category Breakdown (PG 3 – 3 MRK)

Columns: Metric · PG · MRK
1. Valuation Multiples MRK
Forward P/E 24.0x 14.9x
Trailing P/E 25.3x 134.2x
PEG Ratio 4.38x 3.33x
EV / Revenue 4.7x 5.5x
2. Growth & Scale PG
Revenue Growth (YoY) +4.0% +4.7%
Earnings Growth (YoY) +0.8% -12.0%
TTM Revenue (USD) $87.9B $67.4B
Market Cap $389.0B $327.4B
3. Profitability & Quality MRK
Gross Margin 50.6% 75.2%
Operating Margin 24.9% 35.2%
Net Profit Margin 18.2% 3.6%
Return on Equity (ROE) 29.6% 5.1%
4. Balance Sheet & Cash Flow PG
Cash Generation (TTM) $15.3B $14.7B
Cash Flow Margin 17.4% 21.9%
Net Cash / Leverage $23.6B Net Debt (0.71x D/E) $44.2B Net Debt (1.20x D/E)
Dividend Yield 2.52% 2.44%
5. Options & Positioning PG
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 15.0% (12th %ile) 64.7% (79th %ile)
Put/Call OI Skew 0.59x (Call-Skewed) 0.83x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRK
OpEx & R&D Intensity 25.7% of Rev ($22.6B) 40.0% of Rev ($27.0B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Household & Personal Products Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PG (6) vs MRK (4)
Institutional Metric PG MRK Criterion Row Edge
Market Capitalization
Scale
$389.0B $327.4B Larger Scale PG
Trailing P/E Ratio
Valuation
25.3x 134.2x Lower Multiple PG
Forward P/E Ratio
Valuation
24.0x 14.9x Lower Multiple MRK
Revenue Growth (YoY)
Growth
+4.0% +4.7% Higher Growth MRK
Operating Margin (TTM)
Profitability
24.9% 35.2% Higher Margin MRK
Net Profit Margin
Profitability
18.2% 3.6% Higher Margin PG
Return on Equity (ROE)
Capital Efficiency
29.6% 5.1% Higher ROE PG
52-Week Range Position
Momentum
88% ($138–$174) 63% ($94–$157) Stronger Trend PG
Beta / 30D Volatility
Risk Regime
0.02β · 21% Vol 0.23β · 34% Vol Lower Realized Risk PG
Unified Institutional Score
Composite Signal
33.6 / 100 (SELL) 55.3 / 100 (HOLD) Higher Composite MRK
Trailing 12M Revenue (USD)
Operating Scale
$87.9B $67.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
50.6% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
4.38x PEG · 4.7x EV/Rev 3.33x PEG · 5.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$15.3B ($23.6B Net Debt (0.71x D/E)) $14.7B ($44.2B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PG +11.46 pp
PG: +2.28% · MRK: -9.18%
3M Horizon PG +26.77 pp
PG: +15.53% · MRK: -11.24%
6M Horizon PG +8.02 pp
PG: +17.26% · MRK: +9.24%
1Y Horizon MRK +25.45 pp
PG: +15.23% · MRK: +40.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PG Revenue MRK Revenue PG Op. Margin MRK Op. Margin Margin Leader
FY2019 $67.7B $39.1B 8.1% 25.2% MRK
FY2020 $71.0B $41.5B 22.1% 17.0% PG
FY2021 $76.1B $48.7B 23.6% 26.8% MRK
FY2022 $80.2B $59.3B 22.2% 24.5% MRK
FY2023 $82.0B $60.1B 22.1% 0.6% PG
FY2024 $84.0B $64.2B 22.1% 26.7% MRK
FY2025 $84.3B $65.0B 24.3% 28.1% MRK
FY2026 $87.0B N/A 22.7% N/A PG

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PG SURGE
5d in phase · OBV ACCUMULATION
Current IV 15.0%
IV Percentile 12th %ile
Put/Call OI Skew 0.59x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRK CONSOLIDATION
62d in phase · OBV DISTRIBUTION
Current IV 64.7%
IV Percentile 79th %ile
Put/Call OI Skew 0.83x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $173.02 · IV 22.7%

PG vs. MRK: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of PG ($17,302) vs. MRK ($14,446) against risk-defined 5-day vertical and put-wall option structures.

PG Spot $173.02 · IV 22.7%
PG Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $170 / $180 Bull Call Spread

Buy 1x $170C · Sell 1x $180C · 31d

Net Entry $456 Debit
T+5d @ +5% Move +$306 (+67%)
Max Risk / Buffer $456 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $165 / $155 Bull Put Spread

Sell 1x $165P · Buy 1x $155P · 31d

Net Entry $114 Credit
Max Credit / Yield +$114 (+12.9% RoM)
Max Risk / Buffer -5.3% Cushion ($886 Mgn)
5d Edge & Liquidity 78% PoP · Liq A
Simulate 5-Day Payoff →
MRK Spot $144.46 · IV 31.1%
MRK Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $145 / $155 Bull Call Spread

Buy 1x $145C · Sell 1x $155C · 31d

Net Entry $340 Debit
T+5d @ +5% Move +$221 (+65%)
Max Risk / Buffer $340 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $135 / $125 Bull Put Spread

Sell 1x $135P · Buy 1x $125P · 31d

Net Entry $149 Credit
Max Credit / Yield +$149 (+17.5% RoM)
Max Risk / Buffer -7.6% Cushion ($851 Mgn)
5d Edge & Liquidity 78% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PG Moat Profile Scale & Operating Efficiency Moat
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $389.0B market capitalization and 24.9% operating margin.
OpEx & R&D Reinvestment 25.7% of Rev ($22.6B)
90D Engineering Disclosures 0 Published
MRK Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $327.4B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment 40.0% of Rev ($27.0B)
90D Engineering Disclosures 0 Published

Investor FAQ PG vs MRK Key Questions & Quantitative Answers

As of Nov 20, 2026, Merck & Co., Inc. (MRK) is the stronger overall head-to-head candidate over Procter & Gamble Company (PG) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). PG carries a Unified Composite Score of 33.6/100 (SELL) at $169.37 (24.0x Forward P/E, 24.9% operating margin), whereas MRK carries 55.3/100 (HOLD) at $133.72 (14.9x Forward P/E, 35.2% operating margin). Technical & Structure Timing Caution: PG trades in a Markup technical trend (SURGE options phase, RSI 61.0); meanwhile MRK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PG leads the Growth & Scale pillar: PG posts +4.0% YoY revenue growth and +0.8% YoY earnings growth on $87.9B TTM revenue (50.6% gross margin, 24.9% operating margin), compared with MRK at +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PG cumulative revenue shifted +28.6% while MRK shifted +66.2%. In operating R&D and SG&A reinvestment, PG deploys 25.7% of Rev ($22.6B) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($27.0B) (0 disclosures) for MRK.

MRK screens cheaper on headline valuation multiples. PG trades at 24.0x Forward P/E, 25.3x Trailing P/E, 4.38x PEG, and 4.7x EV/Revenue (17.4% FCF margin), whereas MRK trades at 14.9x Forward P/E, 134.2x Trailing P/E, 3.33x PEG, and 5.5x EV/Revenue (21.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PG (29.6% ROE) versus MRK (5.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PG carries 15.0% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.02β · 21% Vol realized risk). By comparison, MRK carries 64.7% implied volatility (79th %ile, Elevated (60th–80th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.23β · 34% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.